Menu
FDA DECISION ·
Keytruda / Keytruda Qlex + Padcev
pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, each with enfortumab vedotin-ejfv · Merck / Astellas
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with muscle-invasive bladder cancer who are candidates for cystectomy. The combination is given before surgery and after cystectomy, expanding the previous cisplatin-ineligible use.
LAMPGEN ANALYSIS
Why it matters
This extends the perioperative option to cisplatin-eligible patients. The two treatment phases make the surgery milestone integral to interpreting trial execution and outcomes.
What research teams should watch
Track the transition from neoadjuvant dosing to cystectomy and the return to adjuvant treatment. Capture surgery delays, safety events and the distinction between clinical and pathologic assessments.
Clinical operations takeaway
Agree on who tracks surgery and treatment milestones across the teams involved. Give delays a defined escalation path and document who decides when the next study activity can proceed.
Scope CTM ownership across study milestonesRelated study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Perioperative muscle-invasive bladder cancerPRIMARY RECORDS